Product Description
Griseofulvin is used to treat skin infections such as jock itch, athlete's foot, and ringworm; and fungal infections of the scalp, fingernails, and toenails. (Sourced from: https://medlineplus.gov/druginfo/meds/a682295.html)
Mechanisms of Action: Tubulin Inhibitor,Mitosis Inhibitor,Fungal Growth Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Bangladesh | Brazil | Canada | Chile | China | Colombia | Cyprus | Dominican Republic | Ecuador | Egypt | France | Germany | Hong Kong | India | Indonesia | Ireland | Italy | Jordan | Korea | Lebanon | Malaysia | Malta | Morocco | New Zealand | Pakistan | Peru | Portugal | Russia | Saudi Arabia | Singapore | Slovenia | South Africa | Sri Lanka | Taiwan | Thailand | Turkey | Ukraine | United Kingdom | United States | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|